Research & Development
USFDA grants approval to Sun Pharmaceutical Industries' CEQUA
17 August 2018 -

It was reported yesterday that the United States Food and Drug Administration (USFDA) has granted approval to India-based Sun Pharmaceutical Industries for its dry eye disease treatment CEQUA (cyclosporine ophthalmic solution) 0.09%.

The product increases tear production in patients with keratoconjunctivitis sicca. It reportedly offers the highest FDA-approved concentration of cyclosporine A and incorporates nanomicellar technology.

Sun Pharma North America CEO, Abhay Gandhi, said: 'Dry Eye Disease represents an area of high unmet medical need, with a significant number of patients who are currently untreated. The US FDA approval of CEQUA represents a long-awaited dry eye treatment option and is an important milestone in the development of Sun's Ophthalmics business. CEQUA, with its novel nanomicellar formulation for a proven dry eye medication, delivers a lipophilic molecule in a clear solution form.'

Login
Username:

Password: